BioTuesdays

Tag - PLRX

Pliant Therapeutics
Markets

SVB starts Pliant Therapeutics at OW: PT $33

SVB Securities initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with an “outperform” rating and price target of $33. The stock closed at $19.22 on July 19. Pliant is a clinical-stage biopharmaceutical company...

July 20, 2022
Pliant Therapeutics
Markets

Cantor starts Pliant Therapeutics at OW; PT $12

Cantor Fitzgerald launched coverage of Pliant Therapeutics (NASDAQ:PLRX) with an “overweight” rating and 12-month price target of $12. The stock closed at $4.93 on May 24. Pliant is developing novel therapies for...

May 25, 2022
Pliant Therapeutics
Markets

HCW starts Pliant Therapeutics at buy; PT $45

H.C. Wainwright initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with a “buy” rating and $45 price target. The stock closed at $16.81 on Nov. 2. Pliant is a clinical-stage biopharmaceutical company focused on the...

November 3, 2021